

AWARD NUMBER: W81XWH-20-1-0610

TITLE: Human Papillomavirus and Lung Cancer

PRINCIPAL INVESTIGATOR: Dawei Li

CONTRACTING ORGANIZATION:

University of Vermont
95 Carrigan Drive, Burlington, VT 05405

REPORT DATE: JANUARY 2021

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Development Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE JANUARY 2021			2. REPORT TYPE Annual		3. DATES COVERED 09/30/2020-01/29/2021	
4. TITLE AND SUBTITLE Human Papillomavirus and Lung Cancer					5a. CONTRACT NUMBER	
					5b. GRANT NUMBER W81XWH-20-1-0610	
					5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Dawei Li E-Mail: lid@health.fau.edu					5d. PROJECT NUMBER LC190467	
					5e. TASK NUMBER	
					5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Vermont (Previously) 95 Carrigan Drive, Burlington, VT 05405 Florida Atlantic University (Currently) 777 Glades Rd, Boca Raton, FL					8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012					10. SPONSOR/MONITOR'S ACRONYM(S)	
					11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited						
13. SUPPLEMENTARY NOTES This report is for grant transfer from University of Vermont to Florida Atlantic University.						
14. ABSTRACT The major goals of the project include: Aim 1: Identify clonal HPV integrations in HIV+ lung cancer; and Aim 2: Identify signatures of HIV+/HPV+ lung cancer. The first step of this project is to obtain specimens (DNA/RNA or tissue) from sample providers (ACSR, an NIIH/NCI-supported publicly available sample repository). The ACSR repository lab is preparing our samples. We expect they will ship the samples to us soon. We will start the proposed sequencing experiment as soon as we receive the specimens. The PI has changed his home institution from University of Vermont to Florida Atlantic University in January 2021. We propose transfer of this grant/project to the new institution. There are no scientific changes regarding the grant transfer expect institution change. We will continue to work on the project as described in our proposal.						
15. SUBJECT TERMS NONE LISTED						
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON	
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC	
Unclassified	Unclassified	Unclassified	Unclassified	14	19b. TELEPHONE NUMBER (include area code)	

TABLE OF CONTENTS

Page

1. Introduction
2. Keywords
3. Accomplishments
4. Impact
5. Changes/Problems
6. Products
7. Participants & Other Collaborating Organizations
8. Special Reporting Requirements
9. Appendices

1. **INTRODUCTION:** *Narrative that briefly (one paragraph) describes the subject, purpose and scope of the research.*

In this project, we aim to sequence the genomes and transcriptomes of human immunodeficiency virus positive lung cancer samples, and use our state-of-the-art analytic approach to identify viral integrations (such as HPV integrations) and virus-associated genetic and immunological features. Completion of this project may have positive impacts on cancer epidemiology and patient survival and will eventually benefit both military personnel and the general public.

2. **KEYWORDS:** *Provide a brief list of keywords (limit to 20 words).*

Lung Cancer; Human papillomavirus (HPV); Viral integration; Deep Sequencing

3. **ACCOMPLISHMENTS:** *The PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency grants official whenever there are significant changes in the project or its direction.*

What were the major goals of the project?

List the major goals of the project as stated in the approved SOW. If the application listed milestones/target dates for important activities or phases of the project, identify these dates and show actual completion dates or the percentage of completion.

The major goals of the project include:

Aim 1: Identify clonal HPV integrations in HIV+ lung cancer (Conduct HPV genotyping of HIV+ lung cancer samples; Perform whole-genome sequencing; Perform clonal integration bioinformatics analyses).

Aim 2: Identify signatures of HIV+/HPV+ lung cancer (Perform RNA Sequencing; Perform RNA Sequencing data analyses; Compare HPV+ and HPV- lung tumors).

What was accomplished under these goals?

For this reporting period describe: 1) major activities; 2) specific objectives; 3) significant results or key outcomes, including major findings, developments, or conclusions (both positive and negative); and/or 4) other achievements. Include a discussion of stated goals not met. Description shall include pertinent data and graphs in sufficient detail to explain any significant results achieved. A succinct description of the methodology used shall be provided. As the project progresses to completion, the emphasis in reporting in this section should shift from reporting activities to reporting accomplishments.

The first step of this project is to obtain specimens (DNA/RNA or tissue) from sample providers (ACSR, an NIIH/NCI-supported publicly available sample repository). Due to the delays by COVID, we have not yet received the specimens from ACSR.

We have completed all required IRB documents. We have also obtained MTA documents with ACSR (we first obtained an MTA between ACSR and University of Vermont. Since the PI changed his institution from University of Vermont to Florida Atlantic University in January 2021, we have then obtained a new MTA between ACSR and Florida Atlantic University). We have also discussed with ACSR about the scientific plans, including sample quantity and quality required for our proposed research. We are currently waiting to receive the proposed specimens from ACSR.

What opportunities for training and professional development has the project provided?

If the project was not intended to provide training and professional development opportunities or there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe opportunities for training and professional development provided to anyone who worked on the project or anyone who was involved in the activities supported by the project. “Training” activities are those in which individuals with advanced professional skills and experience assist others in attaining greater proficiency. Training activities may include, for example, courses or one-on-one work with a mentor. “Professional development” activities result in increased knowledge or skill in one’s area of expertise and may include workshops, conferences, seminars, study groups, and individual study. Include participation in conferences, workshops, and seminars not listed under major activities.

Nothing to Report.

How were the results disseminated to communities of interest?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how the results were disseminated to communities of interest. Include any outreach activities that were undertaken to reach members of communities who are not usually aware of these project activities, for the purpose of enhancing public understanding and increasing interest in learning and careers in science, technology, and the humanities.

Nothing to Report.

What do you plan to do during the next reporting period to accomplish the goals?

If this is the final report, state “Nothing to Report.”

Describe briefly what you plan to do during the next reporting period to accomplish the goals and objectives.

The ACSR repository lab is preparing our proposed samples. We expect that they will ship the samples to us as soon as possible. We will start the proposed sequencing experiment as soon as we receive and prepare the specimens.

- 4. IMPACT:** *Describe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:*

What was the impact on the development of the principal discipline(s) of the project?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how findings, results, techniques that were developed or extended, or other products from the project made an impact or are likely to make an impact on the base of knowledge, theory, and research in the principal disciplinary field(s) of the project. Summarize using language that an intelligent lay audience can understand (Scientific American style).

Nothing to Report.

What was the impact on other disciplines?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how the findings, results, or techniques that were developed or improved, or other products from the project made an impact or are likely to make an impact on other disciplines.

Nothing to Report.

What was the impact on technology transfer?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe ways in which the project made an impact, or is likely to make an impact, on commercial technology or public use, including:

- *transfer of results to entities in government or industry;*
- *instances where the research has led to the initiation of a start-up company; or*
- *adoption of new practices.*

Nothing to Report.

What was the impact on society beyond science and technology?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how results from the project made an impact, or are likely to make an impact, beyond the bounds of science, engineering, and the academic world on areas such as:

- *improving public knowledge, attitudes, skills, and abilities;*
- *changing behavior, practices, decision making, policies (including regulatory policies), or social actions; or*
- *improving social, economic, civic, or environmental conditions.*

Nothing to Report.

- 5. CHANGES/PROBLEMS:** *The PD/PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency grants official whenever there are significant changes in the project or its direction. If not previously reported in writing, provide the following additional information or state, “Nothing to Report,” if applicable:*

Changes in approach and reasons for change

Describe any changes in approach during the reporting period and reasons for these changes. Remember that significant changes in objectives and scope require prior approval of the agency.

The PI recently changed his home institution. He moved from University of Vermont to Florida Atlantic University in January 2021 (as discussed by emails recently). We propose to transfer this grant/project to the new institution. There are no scientific changes regarding the grant transfer. We will continue to work on the project as described in our proposal.

Actual or anticipated problems or delays and actions or plans to resolve them

Describe problems or delays encountered during the reporting period and actions or plans to resolve them.

In addition to the PI's institutional change (which should not have any negative impact on this project), we anticipate a delay of the proposed project timeline due to COVID. Specifically, we are still waiting to receive the proposed specimens from the ACSR sample repository. We are actively communicating with the ACSR repository. As soon as we receive the samples, we will perform the proposed sequencing experiments and data-analysis.

Changes that had a significant impact on expenditures

Describe changes during the reporting period that may have had a significant impact on expenditures, for example, delays in hiring staff or favorable developments that enable meeting objectives at less cost than anticipated.

Because we have not yet received samples due to COVID-induced delays, we have not yet performed proposed sequencing experiments. We anticipate possible no-cost-extension if needed.

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Describe significant deviations, unexpected outcomes, or changes in approved protocols for the use or care of human subjects, vertebrate animals, biohazards, and/or select agents during the reporting period. If required, were these changes approved by the applicable institution committee (or equivalent) and reported to the agency? Also specify the applicable Institutional Review Board/Institutional Animal Care and Use Committee approval dates.

Significant changes in use or care of human subjects

No human subjects research will be performed to complete the Statement of Work.

In this project, we will use existing de-identified human samples. We have obtained non-human-subject IRB approvals.

Significant changes in use or care of vertebrate animals

No animal research.

Significant changes in use of biohazards and/or select agents

NA.

6. PRODUCTS: *List any products resulting from the project during the reporting period. If there is nothing to report under a particular item, state “Nothing to Report.”*

- **Publications, conference papers, and presentations**

Report only the major publication(s) resulting from the work under this award.

Journal publications. *List peer-reviewed articles or papers appearing in scientific, technical, or professional journals. Identify for each publication: Author(s); title; journal; volume: year; page numbers; status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

Two papers in 2021

1. Mathkar PP, Chen X*, Sulovari A, **Li D***. Characterization of hepatitis B virus integrations identified in hepatocellular carcinoma genomes. *Viruses*. 2021 Feb 4;13(2):245. PMID: 33557409. (* **corresponding author**).
2. Chen X, **Li D***. Sequencing facility and DNA source associated patterns of virus-mappable reads in whole-genome sequencing data. *Genomics*. 2021 Jan;113(1 Pt 2):1189-1198. PMID: 33301893. (* **corresponding author**).

(Acknowledgment of this grant (LC190467) is shown in papers' Funding section.)

Books or other non-periodical, one-time publications. *Report any book, monograph, dissertation, abstract, or the like published as or in a separate publication, rather than a periodical or series. Include any significant publication in the proceedings of a one-time conference or in the report of a one-time study, commission, or the like. Identify for each one-time publication: author(s); title; editor; title of collection, if applicable; bibliographic information; year; type of publication (e.g., book, thesis or dissertation); status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

Nothing to Report.

Other publications, conference papers and presentations. *Identify any other publications, conference papers and/or presentations not reported above. Specify the status of the publication as noted above. List presentations made during the last year (international, national, local societies, military meetings, etc.). Use an asterisk (*) if presentation produced a manuscript.*

Nothing to Report.

- **Website(s) or other Internet site(s)**

List the URL for any Internet site(s) that disseminates the results of the research activities. A short description of each site should be provided. It is not necessary to include the publications already specified above in this section.

Nothing to Report.

- **Technologies or techniques**

Identify technologies or techniques that resulted from the research activities. Describe the technologies or techniques were shared.

Nothing to Report.

- **Inventions, patent applications, and/or licenses**

Identify inventions, patent applications with date, and/or licenses that have resulted from the research. Submission of this information as part of an interim research performance progress report is not a substitute for any other invention reporting required under the terms and conditions of an award.

Nothing to Report.

- **Other Products**

Identify any other reportable outcomes that were developed under this project. Reportable outcomes are defined as a research result that is or relates to a product, scientific advance, or research tool that makes a meaningful contribution toward the understanding, prevention, diagnosis, prognosis, treatment and /or rehabilitation of a disease, injury or condition, or to improve the quality of life. Examples include:

- *data or databases;*
- *physical collections;*
- *audio or video products;*
- *software;*
- *models;*
- *educational aids or curricula;*
- *instruments or equipment;*
- *research material (e.g., Germplasm; cell lines, DNA probes, animal models);*
- *clinical interventions;*
- *new business creation; and*
- *other.*

Nothing to Report.

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Provide the following information for: (1) PDs/PIs; and (2) each person who has worked at least one person month per year on the project during the reporting period, regardless of the source of compensation (a person month equals approximately 160 hours of effort). If information is unchanged from a previous submission, provide the name only and indicate “no change”.

Example:

Name: Mary Smith
Project Role: Graduate Student
Researcher Identifier (e.g. ORCID ID): 1234567
Nearest person month worked: 5

Contribution to Project: Ms. Smith has performed work in the area of combined error-control and constrained coding.
Funding Support: The Ford Foundation (Complete only if the funding support is provided from other than this award.)

Name: Dawei Li
Project Role: PI
Nearest person month worked: 1
Contribution to Project: Li has prepared and tested the proposed analytic platform in similar other existing datasets and the proposed platform is now ready to continue this project.

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

If the active support has changed for the PD/PI(s) or senior/key personnel, then describe what the change has been. Changes may occur, for example, if a previously active grant has closed and/or if a previously pending grant is now active. Annotate this information so it is clear what has changed from the previous submission. Submission of other support information is not necessary for pending changes or for changes in the level of effort for active support reported previously. The awarding agency may require prior written approval if a change in active other support significantly impacts the effort on the project that is the subject of the project report.

The PI has received new grants since the beginning of this project (such as a new NIH/NIAID R21). The details of the full grant information are described in “PI Previous/Current/Pending Support.pdf”, which we have submitted during the grant transfer paperwork. The PI’s other grants have no overlaps with this project. We just also know that the Co-I (Dr. Jian Cao) has just completed one grant and received a new institutional/internal small grant. We are also working to submit his updated “Previous/Current/Pending Support Jian Cao.pdf” document.

What other organizations were involved as partners?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe partner organizations – academic institutions, other nonprofits, industrial or commercial firms, state or local governments, schools or school systems, or other organizations (foreign or domestic) – that were involved with the project. Partner organizations may have provided financial or in-kind support, supplied facilities or equipment, collaborated in the research, exchanged personnel, or otherwise contributed.

Provide the following information for each partnership:

Organization Name:

Location of Organization: (if foreign location list country)

Partner’s contribution to the project (identify one or more)

- *Financial support;*
- *In-kind support (e.g., partner makes software, computers, equipment, etc., available to project staff);*
- *Facilities (e.g., project staff use the partner’s facilities for project activities);*
- *Collaboration (e.g., partner’s staff work with project staff on the project);*
- *Personnel exchanges (e.g., project staff and/or partner’s staff use each other’s facilities, work at each other’s site); and*
- *Other.*

Organization Name: AIDS and Cancer Specimen Resource (ACSR)

Location of Organization: San Francisco, CA

Partner's contribution to the project: Working to provide us sample specimens.

8. SPECIAL REPORTING REQUIREMENTS

COLLABORATIVE AWARDS: *For collaborative awards, independent reports are required from BOTH the Initiating Principal Investigator (PI) and the Collaborating/Partnering PI. A duplicative report is acceptable; however, tasks shall be clearly marked with the responsible PI and research site. A report shall be submitted to <https://ebrap.org/eBRAP/public/index.htm> for each unique award.*

QUAD CHARTS: *If applicable, the Quad Chart (available on <https://www.usamraa.army.mil/Pages/Resources.aspx>) should be updated and submitted with attachments.*

9. **APPENDICES:** *Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.*